Analysis of convergent effects of doxorubicin, quercetin and menadione in treatments of human leukemia Jurkat T cells

12^th World Cancer Conference

September 26-28, 2016 London, UK

Oana Elena Baran, Ioana Teodora Tofolean, Maria Catalina Ceausescu and Constanta Ganea

Carol Davila University of Medicine and Pharmacy, Romania

Posters & Accepted Abstracts: J Cancer Sci Ther

Abstract :

Given the major diversity of cancer forms, development of treatments with specific functions is of great importance. In this in vitro study, leukemia Jurkat cells interactions with antitumoral antibiotic Doxorubicin (DOX) were investigated, and their modulation by flavonoid Quercetin (QC) and Menadione (MD). Cell cycle, apoptosis/necrosis and oxidative status were assessed by flow cytometry. DOX acts on malignant cells via cell-cycle arrest, mitochondrial depolarization and oxidative stress. Cellular viability dose-dependently decreased after 18 h and 48 h exposure to DOX (IC50=571 nM and 93 nM, respectively), while the sub-G0 cell fraction increased (IC50=385 nM and 128 nM, respectively). Also, 0.1 �¼M and 1 �¼M DOX arrested the cell cycle in G2/M (63% cells) and S phase (70%), respectively. In 18 h treatments, the 15 �¼M equimolar QC/MD combination produced by itself 52% cell death rate, by oxidative stress generation and apoptosis induction, and enhanced DOX cytotoxicity, dramatically decreasing the viable cell fraction (IC50=1.25 �¼M). 15 �¼M QC with 7.5 �¼M MD produced 69% viable cells; association with DOX exhibited additive cytotoxicity (IC50=2.26 �¼M). 48 h exposures further enhanced the effects. Addition of QC/MD up to 7.5 �¼M and 2.5 �¼M, respectively, to the 0.1 �¼M and 1 �¼M DOX-plan, increased the S-cell fraction, with higher levels progressively increasing the G0/G1 cell fraction. Therefore, QC/MD combination appears to be a good addition to DOX-treatments.

Biography :

Oana Elena Baran is an under-graduate student at Carol Davila University of Medicine and Pharmacy, Romania.

Email: oana.baran@gmail.com